Endocrine Abstracts

Diabetes is a chronic disease that is often accompanied by multiple comorbidities and health complications such as overweight/obesity. In the late years therapies improving glycemic control while reducing body weight have become a convenient choice to treat diabetes. One of those therapies are GLP 1 receptor agonists. Dulaglutide allows for a once weekly dosing which might improve compliance; moreover its new application device ease the injection. We show the results of HbA1c and weight evolution after starting dulaglutide 1.5 mg weekly in 60 patients (all of them were on metformin and a second drug). Women represented the 42% and the medium age was 59±7 years. We show data after 6 months on dulaglutide. Initial Hba1c was 8.3% (±1.2). After 6 months it was 7.2% (±1). Initial weight was 107.7 kg (±12). After 6 months it was 101.5 kg (±16). Our results showed an average reduction of HbA1c of 1.1% and average reduction of weight of 6.2 kg. 25% of the patients showed sickness and only a 5% vomits. Only 2 patients had to stop the therapy. There were no other side effects. None of the patients complained about pain or inconvenience related to the injection and all of them found it painless. All the patients rated positively the one weekly dosing. Dulaglutide added to the previous treatment improved glycaemic control in DM2 patients. Dulaglutide added to the previous treatment produced weight loss in DM2 patients. The main side effect was sickness, but it was well tolerated in most of the patients and the therapy was not discontinued. The one weekly dosing and the painless administration was positively rated by all the patients.